Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM)

Price 297.00p on 26-04-2024 at 14:07:15
Change -7.00p -2.3%
Buy 302.00p
Sell 296.00p
Buy / Sell HCM Shares
Last Trade: Sell 445.00 at 297.00p
Day's Volume: 91,293
Last Close: 304.00p
Open: 312.00p
ISIN: KYG4672N1198
Day's Range 297.00p - 312.00p
52wk Range: 173.60p - 338.00p
Market Capitalisation: £2,535m
VWAP: 305.11195p
Shares in Issue: 854m

Recent Trades History Hutchmed (HCM)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 445 297.00p Automatic Execution
14:00:36 - 26-Apr-24
Sell* 1,055 297.00p Automatic Execution
14:00:36 - 26-Apr-24
Sell* 500 297.00p Automatic Execution
14:00:36 - 26-Apr-24
Sell* 1,000 297.00p Automatic Execution
14:00:36 - 26-Apr-24
Sell* 555 297.00p Automatic Execution
14:00:36 - 26-Apr-24
Sell* 500 297.00p Automatic Execution
14:00:36 - 26-Apr-24
Sell* 1,000 297.00p Automatic Execution
14:00:36 - 26-Apr-24
Sell* 500 297.00p Automatic Execution
14:00:36 - 26-Apr-24
Sell* 1,000 300.00p Automatic Execution
13:56:56 - 26-Apr-24
Buy* 945 300.00p Automatic Execution
13:54:13 - 26-Apr-24

Share Price History for Hutchmed

Time period:
to
Date Open High Low Close Volume

Share News for Hutchmed

Hutchmed endometrial cancer treatment application accepted for review

2nd Apr 2024 10:32

(Alliance News) - Hutchmed (China) Ltd on Tuesday jointly announced with Innovent Biologics that their new drug application for the combined fruquintinib and sintilimab treatment for endometrial cancer has been granted priority review by the China National Medical Products Administration. Read More

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

2nd Apr 2024 08:05

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later. Read More

Hutchmed lung cancer treatment accepted for review in China

28th Mar 2024 11:08

(Alliance News) - Hutchmed (China) Ltd on Thursday said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration. Read More

LONDON BRIEFING: JD Sports backs outlook; Spirent accepts new offer

28th Mar 2024 08:08

(Alliance News) - Stocks in London traded higher early on Thursday in the final trading day of a holiday-shortened week, despite some hawkish words from a US central banker. Read More

Hutchmed begins registration stage for sovleplenib phase 2/3 trial

22nd Mar 2024 10:09

(Alliance News) - Hutchmed (China) Ltd on Friday said it initiated the registration stage of the phase 2/3 clinical trial for sovleplenib, its warm antibody autoimmune hemolytic anemia treatment. Read More

FTSE 100 Latest
Value8,138.60
Change59.74

Login to your account

Forgot Password?

Not Registered